Retraction notice to 'Molecular based treatment of oral cancer' [Oral Oncol. 39 (2003) 749-758] (DOI:10.1016/S1368-8375(03)00098-8);Molecular based treatment of oral cancer

Oral Oncology

Volumn 39, Issue 8, 2003, Pages 749-758

  Sudbø, Jon ^a   Bryne, Magne ^b   Mao, Li ^c   Lotan, Reuben ^c   Reith, Albrecht ^a   Kildal, Wanja ^a   Davidson, Ben ^b   Søland, Tine M ^b   Lippman, Scott M ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoprevention; Combinatorial therapy; COX 2; EGFR; Molecular targeting

Indexed keywords

ARACHIDONIC ACID; BEXAROTENE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FENRETINIDE; INDOMETACIN; LIPOXYGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PELITINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUINOLINE DERIVATIVE; SULINDAC; TRANSFORMING GROWTH FACTOR BETA2;

AGE DISTRIBUTION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; EUROPE; HUMAN; MOLECULAR DYNAMICS; MOUTH CARCINOMA; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED STATES;

EID: 1642358424     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.01.004     Document Type: Erratum

References (97)

1. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin. 49:1999;33-64.
2. Annertz K., Anderson H., Biorklund A., Moller T., Kantola S., Mork J.et al. Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer. 101:2002;95-99.
3. Macfarlane G.J., Boyle P., Scully C. Rising mortality from cancer of the tongue in young Scottish males. Lancet. 2:1987;912.
4. Macfarlane G.J., Boyle P., Evstifeeva T.V., Robertson C., Scully C. Rising trends of oral cancer mortality among males worldwide. the return of an old public health problem Cancer Causes Control. 5:1994;259-265.
5. Macfarlane G.J., Evstifeeva T.V., Robertson C., Boyle P., Scully C. Trends of oral cancer mortality among females worldwide. Cancer Causes Control. 5:1994;255-258.
6. Newman A.N., Rice D.H., Ossoff R.H., Sisson G.A. Carcinoma of the tongue in persons younger than 30 years of age. Arch Otolaryngol. 109:1983;302-304.
7. Brunin F., Mosseri V., Jaulerry C., Point D., Cosset J.M., Rodriguez J. Cancer of the base of the tongue. past and future Head Neck. 21:1999;751-759.
8. Mork J. Forty years of monitoring head and neck cancer in Norway - no good news. Anticancer Res. 18:1998;3705-3708.
9. O'Shaughnessy J.A., Kelloff G.J., Gordon G.B., Dannenberg A.J., Hong W.K., Fabian C.J.et al. Treatment and prevention of intraepithelial neoplasia. an important target for accelerated new agent development Clin Cancer Res. 8:2002;314-346.
10. Lippman S.M., Lee J.J., Sabichi A.L. Cancer chemoprevention. progress and promise J Natl Cancer Inst. 90:1998;1514-1528.
11. Smith R.A., Cokkinides V., von Eschenbach A.C., Levin B., Cohen C., Runowicz C.D.et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 52:2002;8-22.
12. Smith R.A., von Eschenbach A.C., Wender R., Levin B., Byers T., Rothenberger D.et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 - testing for early lung cancer detection. CA Cancer J Clin. 51:2001;38-75.
13. Johnson S.C., Gerber J.G. Advances in HIV/AIDS therapy. Adv Intern Med. 45:2000;1-40.
14. Sporn M.B., Suh N. Chemoprevention. an essential approach to controlling cancer Nat Rev Cancer. 2:2002;537-543.
15. Boardman L.A. Heritable colorectal cancer syndromes. recognition and preventive management Gastroenterol Clin North Am. 31:2002;1107-1131.
16. Lippman S.M., Hong W.K. Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res, 8: 314-346, 2002. Clin Cancer Res. 8:2002;305-313.
17. Lippman S.M., Hong W.K. Cancer prevention science and practice. Cancer Res. 62:2002;5119-5125.
18. Sporn M.B. The war on cancer. a review Ann N Y Acad Sci. 833:1997;137-146.
19. Parkin D.M. Global cancer statistics in the year. Lancet Oncol. 2001:2000;2. 533-543.
20. Mork J., Thoresen S., Faye-Lund H., Langmark F., Glattre E. Head and neck cancer in Norway. A study of the quality of the Cancer Registry of Norway's data on head and neck cancer for the period 1953-1991. APMIS. 103:1995;375-382.
21. Schwartz G.J., Mehta R.H., Wenig B.L., Shaligram C., Portugal L.G. Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck. 22:2000;34-41.
22. Xi S., Grandis J.R. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res. 82:2003;11-16.
23. Slaughter D.P., Southwick H.W., Smejkal W. Field cancerization in oral stratified squamous epithelium. clinical implications of multicentric origin Cancer. 6:1953;963-968.
24. Hong W.K. Multiple primary squamous cell carcinoma of the head and neck. Am J Clin Oncol. 10:1987;182-183.
25. Nikitakis N.G., Siavash H., Hebert C., Reynolds M.A., Hamburger A.W., Sauk J.J. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br J Cancer. 87:2002;1396-1403.
26. Nikitakis N.G., Hebert C., Lopes M.A., Reynolds M.A., Sauk J.J. PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 98:2002;817-823.
27. Nikitakis N.G., Hamburger A.W., Sauk J.J. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res. 62:2002;1004-1007.
28. Jaeckel E.C., Raja S., Tan J., Das S.K., Dey S.K., Girod D.A.et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 127:2001;1253-1259.
29. Giercksky K.E. COX-2 inhibition and prevention of cancer. Best Pract Res Clin Gastroenterol. 15:2001;821-833.
30. Dajani E.Z., Agrawal N.M. Selective COX-2 inhibitors and gastrointestinal mucosal injury. pharmacological and therapeutic considerations J Assoc Acad Minor Phys. 11:2000;28-31.
31. Dannenberg A.J., Altorki N.K., Boyle J.O., Dang C., Howe L.R., Weksler B.B.et al. Cyclo-oxygenase 2. a pharmacological target for the prevention of cancer Lancet Oncol. 2:2001;544-551.
32. Dannenberg A.J., Altorki N.K., Boyle J.O., Lin D.T., Subbaramaiah K. Inhibition of cyclooxygenase-2. an approach to preventing cancer of the upper aerodigestive tract Ann NY Acad Sci. 952:2001;109-115.
33. Milas I., Komaki R., Hachiya T., Bubb R.S., Ro J.Y., Langford L.et al. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res. 9:2003;1070-1076.
34. Suarez P., Batsakis J.G., El-Naggar A.K. Leukoplakia. still a gallimaufry or is progress being made? - A review Adv Anat Pathol. 5:1998;137-155.
35. Axell T., Pindborg J.J., Smith C.J., van dW I. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, 18-21 May 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 25:1996;49-54.
36. Waldron C.A., Shafer W.G. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer. 36:1975;1386-1392.
37. Warnakulasuriya S. Histological grading of oral epithelial dysplasia. revisited J Pathol. 194:2001;294-297.
38. Sudbø J., Kildal W., Risberg B., Koppang H.S., Danielsen H.E., Reith A. DNA content as a prognostic marker in patients with oral leukoplakias. N Engl J Med. 344:2001;1270-1278.
39. Sudbø J., Kildal W., Johannessen A.C., Koppang H.S., Sudbø A., Danielsen H.E.et al. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol. 20:2002;456-462.
40. Sudbø J., Ried T., Bryne M., Kildal W., Danielsen H.E., Reith A. Abnormal DNA content predicts the occurence of carcinomas in non-dysplastic oral white patches. Oral Oncol. 37:2001;558-565.
41. Lind P.O. Malignant transformation in oral leukoplakia. Scand J Dent Res. 95:1987;449-455.
42. Lotan R., Xu X.C., Lippman S.M., Ro J.Y., Lee J.S., Lee J.J.et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 332:1995;1405-1410.
43. Cohen E.E., Vokes E.E. Searching for a standard. J Clin Oncol. 20:2002;359-361.
44. Pindborg J.J., Reichart P.A., Smith C.J., van der Waal J. Histological typing of cancer and precancer of the oral mucosa. 2nd ed:1997;Springer, London.
45. Pindborg J.J. Clinical relevance of precancerous lesions of oral mucosa. Recent Results Cancer Res. 134:1994;9-16.
46. Kleinman D.V., Swango P.A., Pindborg J.J., Gupta P. Toward assessing trends in oral mucosal lesions. lessons learned from oral cancer Adv Dent Res. 7:1993;32-41.
47. Rosin M.P., Lam W.L., Poh C., Le N.D., Li R.J., Zeng T.et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 62:2002;6447-6450.
48. Zhang L., Rosin M.P. Loss of heterozygosity. a potential tool in management of oral premalignant lesions? J Oral Pathol Med. 30:2001;513-520.
49. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S.et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 2:1996;682-685.
50. Mao L. Can molecular assessment improve classification of head and neck premalignancy? Clin Cancer Res. 6:2000;321-322.
51. Sudbø J., Bryne M., Johannessen A.C., Kildal W., Danielsen H.E., Reith A. Comparison of histological grading and large scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia. Journal of Pathology. 194:2001;303-310.
52. Aspirin New uses for an old standby. Mayo Clin Health Lett. 20:2002;7.
53. Janne P.A., Mayer R.J. Chemoprevention of colorectal cancer. N Engl J Med. 342:2000;1960-1968.
54. Appleton D.R., Thomson P.J., Donaghey C.E., Potten C.S., McGurk M. Simulation of cell proliferation in mouse oral epithelium, and the action of epidermal growth factor: evidence for a high degree of synchronization of the stem cells. Cell Prolif. 35(Suppl. 1):2002;68-77.
55. Hsu S., Borke J.L., Lewis J.B., Singh B., Aiken A.C., Huynh C.T.et al. Transforming growth factor beta 1 dysregulation in a human oral carcinoma tumour progression model. Cell Prolif. 35:2002;183-192.
56. Manning G., Plowman G.D., Hunter T., Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci. 27:2002;514-520.
57. Courtneidge S.A., Plowman G.D. The discovery and validation of new drug targets in cancer. Curr Opin Biotechnol. 9:1998;632-636.
58. DuBois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B.et al. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073.
59. Krause W.F., DuBois R.N. The molecular basis for prevention of colorectal cancer. Clin Colorectal Cancer. 1:2001;47-54.
60. Gupta R.A., DuBois R.N. Controversy. PPARgamma as a target for treatment of colorectal cancer Am. J. Physiol. Gastrointest Liver Physiol. 283:2002;G266-G269.
61. Turini M.E., DuBois R.N. Cyclooxygenase-2. a therapeutic target Annu. Rev. Med. 53:2002;35-57.
62. Araki Y., Okamura S., Hussain S.P., Nagashima M., He P., Shiseki M.et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 63:2003;728-734.
63. Grandis J.R., Tweardy D.J., Melhem M.F. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 4:1998;13-20.
64. Grandis J.R., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M.et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 90:1998;824-832.
65. Carraway K.L., Ramsauer V.P., Haq B., Carothers Carraway C.A. Cell signaling through membrane mucins. Bioessays. 25:2003;66-71.
66. Luo X., Gong X., Tang C.K. Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. Int J Cancer. 104:2003;716-721.
67. Kim J., Ahn S., Guo R., Daaka Y. Regulation of epidermal growth factor receptor internalization by g protein-coupled receptors. Biochemistry. 42:2003;2887-2894.
68. Di Gennaro E., Barbarino M., Bruzzese F., De Lorenzo S., Caraglia M., Abbruzzese A.et al. Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol. 195:2003;139-150.
69. Normanno N., Maiello M.R., De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). simple drugs with a complex mechanism of action? J Cell Physiol. 194:2003;13-19.
70. Nagler R.M., Kerner H., Laufer D., Ben Eliezer S., Minkov I., Ben Itzhak O. Squamous cell carcinoma of the tongue. the prevalence and prognostic roles of p53, Bcl-2, c-erbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study Cancer Lett. 186:2002;137-150.
71. Wissner A., Overbeek E., Reich M.F., Floyd M.B., Johnson B.D., Mamuya N.et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem. 46:2003;49-63.
72. Wissner A., Brawner Floyd M.B., Rabindran S.K., Nilakantan R., Greenberger L.M., Shen R.et al. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles. analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents Bioorg Med Chem Lett. 12:2002;2893-2897.
73. Boschelli D.H. 4-anilino-3-quinolinecarbonitriles. an emerging class of kinase inhibitors Curr Top Med Chem. 2:2002;1051-1063.
74. Huang Y, Kim SO, Jiang J, Frank SJ. Growth hormone-induced phosphorylation of EGF receptor in 3T3-F442A cells: modulation of EGF-induced trafficking and signaling. J Biol Chem 2003;278(21)18902-13.
75. Piiper A., Lutz M.P., Cramer H., Elez R., Kronenberger B., Dikic I.et al. Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 301:2003;848-854.
76. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A.et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 6:2000;1024-1028.
77. Neumann A.A., Reddel R.R. Telomere maintenance and cancer - look, no telomerase. Nat Rev Cancer. 2:2002;879-884.
78. Saldanha S.N., Andrews L.G., Tollefsbol T.O. Assessment of telomere length and factors that contribute to its stability. Eur J Biochem. 270:2003;389-403.
79. Tominaga K., Olgun A., Smith J.R., Pereira-Smith O.M. Genetics of cellular senescence. Mech Ageing Dev. 123:2002;927-936.
80. Helder M.N., Wisman G.B., van der Zee G.J. Telomerase and telomeres. from basic biology to cancer treatment Cancer Invest. 20:2002;82-101.
81. Gordon K.E., Ireland H., Roberts M., Steeghs K., McCaul J.A., MacDonald D.G.et al. High levels of telomere dysfunction bestow a selective disadvantage during the progression of human oral squamous cell carcinoma. Cancer Res. 63:2003;458-467.
82. Nam N.H., Parang K. Current targets for anticancer drug discovery. Curr Drug Targets. 4:2003;159-179.
83. Shay J.W., Wright W.E. Telomerase. a target for cancer therapeutics Cancer Cell. 2:2002;257-265.
84. Longchampt E., Lebret T., Molinie V., Bieche I., Botto H., Lidereau R. Detection of telomerase status by semiquantitative and in situ assays, and by real-time reverse transcription-polymerase chain reaction (telomerase reverse transcriptase) assay in bladder carcinomas. BJU Int. 91:2003;567-572.
85. Li S.Q., Sheng Z.M., Baili Y., Erozan Y.S., O'Leary T.J. Detection of hTERT mRNA in colonic brush specimens as an adjunct to cytopathologic diagnosis of colonic adenocarcinoma. Acta Cytol. 46:2002;1069-1074.
86. Blasco M.A. Mouse models to study the role of telomeres in cancer, aging and DNA repair. Eur J Cancer. 38:2002;2222-2228.
87. Soria J.C., Moon C., Wang L., Hittelman W.N., Jang S.J., Sun S.Y.et al. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst. 93:2001;1257-1263.
88. Maida Y., Kyo S., Kanaya T., Wang Z., Yatabe N., Tanaka M.et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene. 21:2002;4071-4079.
89. Mitchell M.S. Cancer vaccines, a critical review - part II. Curr Opin Investig Drugs. 3:2002;150-158.
90. Ruffini P.A., Biragyn A., Kwak L.W. Recent advances in multiple myeloma immunotherapy. Biomed Pharmacother. 56:2002;129-132.
91. Treon S.P., Raje N., Anderson K.C. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol. 27:2000;598-613.
92. Bei R., Pompa G., Vitolo D., Moriconi E., Ciocci L., Quaranta M.et al. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol. 195:2001;343-348.
93. Song J.I., Lango M.N., Hwang J.D., Drenning S.D., Zeng Q., Lamph W.W.et al. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res. 61:2001;5919-5925.
94. Banerjee A.G., Gopalakrishnan V.K., Bhattacharya I., Vishwanatha J.K. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol Cancer Ther. 1:2002;1265-1271.
95. Sumitani K., Kamijo R., Toyoshima T., Nakanishi Y., Takizawa K., Hatori M.et al. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med. 30:2001;41-47.
96. Reith A., Sudbo J. Impact of genomic instability in risk assessment and chemoprevention of oral premalignancies. Int J Cancer. 101:2002;205-209.
97. Haroske G., Baak J.P., Danielsen H., Giroud F., Gschwendtner A., Oberholzer M.et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol. 23:2001;89-95.